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and treatment practices and predicted a substantial long-term
beneﬁt of prophylactic cervical cancer vaccination. The vaccine
may be considered to be cost-effective under a number of assump-
tions and vaccination age groups.
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OBJECTIVES: Oseltamivir has been stockpiled for emerging
threat by new inﬂuenza pandemic. Recent studies report some-
what possibility of the virus emerging resistant to oseltamivir. The
purpose of this study is to evaluate the cost-effectiveness of
oseltamivir for inﬂuenza in Japan with considering the com-
plications and the emergence of oseltamivir-resistant virus.
METHODS: A cost-effectiveness analysis was performed by deci-
sion tree using evidence from the Japanese clinical trial and the
NICE, UK, systematic reviews. The decision tree models a patient
presenting with inﬂuenza likely illness and facing the alternative
treatments: rapid diagnostic testing followed by treatment with
oseltamivir or a comparator which goes with conventional treat-
ments. The decision tree visualized morbidity and mortality with
complications such as ill states needed for antibiotics and hospi-
talization due to pneumonia. The analysis included assessment of
not only directmedical costs but also productivity loss. Costs were
derived from published literature and the statistics in DPC (Diag-
nosis Procedure Combination) system in Japan. RESULTS: Con-
sidering the productivity loss during inﬂuenza and complications,
oseltamivir cost JPY150,703, and the comparator, JPY163,415
per QALY. When the prevalence was in the low range of 10%
through 40%, the dominance of oseltamivir vanished. The incre-
mental cost-effectiveness ratio (ICER) of oseltamivir versus com-
parator was JPY398,571 per QALY. Considering the productivity
loss, however, the ICER for oseltamivir turned to be negative,
simple dominant, JPY-2,345,714 per QALY. Regarding the virus
emerging resistant to the drug, we found the dominance of osel-
tamivir vanish if the emerging rate becomes more than 27%.
Sensitivity analysis also suggested that the emerging rate of the
drug-resistant viruswasmore sensitive in the inﬂuenza peri-season
(prevalence: 40–60%). CONCLUSION: The use of oseltamivir
for inﬂuenza was so far recommended as cost-effectiveness in
Japan. However, the advantage of oseltamivir is affected by both
the prevalence and emerging rate of the oseltamivir-resistant virus.
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OBJECTIVES: HPV vaccination is recommended in Germany
for adolescent girls. The objective of this research was to estimate
for Germany, the cost-effectiveness of a candidate prophylactic
cervical cancer vaccine with potential cross-protection beneﬁts.
METHODS: A Markov model based upon the natural history of
HPV and cervical cancer was developed to simulate transitions
between health states: Normal, HPV, Cervical Intraepithelial
Neoplasia (CIN), Cervical Cancer (CC) stages 1 to 4, and death.
Using a lifetime simulation of 12-year old girls, the model was
adapted for country-speciﬁc epidemiological data: age-speciﬁc
HPV prevalence, HPV type distribution in cervical disease,
prevalence of pre-cancerous lesions, and age-speciﬁc CC inci-
dence and mortality. Country-speciﬁc screening practices and
costs were used with a discount rate of 4% on costs, 1.5% on
outcomes. Published efﬁcacy rates were used for the candidate
vaccine including a potential cross-protection beneﬁt (i.e., addi-
tional efﬁcacy against oncogenic HPV types 31 and 45). Sensi-
tivity analyses were performed on costs, discount rates, efﬁcacies,
cross-protection, and age at vaccination. RESULTS: Reductions
in CC and related deaths were predicted to be 81% (80% mor-
tality) following vaccination of 12 year old girls. The correspond-
ing cost per life-year gained ranged from €19,600 to €20,700
respectively, depending upon whether the analysis was conducted
from a societal or health-care payer perspective. When consider-
ing quality of life beneﬁts, the vaccine showed a cost per quality-
adjusted life-year of €14,700 (societal) to €15,500 (payer).
Results were most sensitive to assumptions about discount rates
and age at vaccination. For cohorts of 18, and 25-year-old
women, vaccination has estimated cost per QALYs of €16,100
and €18,800 (societal), and €15,300 and €18,000 (payer), respec-
tively. CONCLUSION: Prophylactic vaccination against CC
with a candidate HPV 16/18 vaccine is a cost-effective method of
reducing precancerous cervical lesions, cervical cancer incidence
and mortality in Germany.
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OBJECTIVES: This study estimates the cost and the effectiveness
of brivudine and aciclovir in the treatment of Herpes Zoster
(HZ) in Spain focusing on the number of post herpetic neuralgia
(PHN) avoided cases. METHODS: A cost-effectiveness decision
model was built from clinical results obtained in the double-blind
controlled trail that compared brivudine and aciclovir. The ana-
lytic model estimates the mean cost per patient treated with HZ
and the mean cost per PHN avoided case. Time horizon of the
study considered HZ acute treatment period (7 days) plus PHN
treatment period (between 90 and 180 days). This decision
model also considers the incidence rate of HZ in Spain for
patients older than 50 years, clinical drug effectiveness, HZ and
PHN direct medical costs and three PHN treatments options
(tramadol, gabapentine and pregabaline). RESULTS: It has been
estimated that 109.982 patients with HZ would be treated in
Spain each year. If all those patients would be treated with
brivudine, then 8,976 NPH cases could be avoided if the same
number of patients would receive aciclovir. Mean cost per treated
patient would be lower with brivudine for all PHN treatment
options. Overall, brivudine has a greater effectiveness and a
lower cost per treated patient, thus estimated direct medical cost
per PHN avoided case would be reduced in 33€ when the PHN
patient is treated with tramadol, 35€ for gabapentine and 71€ for
pregabaline. CONCLUSION: Results from base-case and sensi-
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tivity analysis indicate that brivudine is a cost-effective treatment
for HZ when it is compared to aciclovir in the Spanish setting.
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OBJECTIVES: In considering the inclusion of healthy adults
aged 50–64 in the yearly inﬂuenza vaccination scheme, the Dutch
ministry of health had issued a study on the balance of costs and
effects of vaccination compared to no vaccination, as well as the
budget impact. METHODS: An available decision model was
adapted to assess the cost-effectiveness of inﬂuenza vaccination
for healthy adults assuming average inﬂuenza epidemic severity.
Excess cardiovascular complications leading to hospital admis-
sions were accounted for. Both the peri-season and the summer
were used as reference period to estimate the (excess) disease
incidence and the inﬂuenza related complications. Direct medical
costs as well as losses in productivity were accounted for.
RESULTS: When using the peri-seasonal period as the reference
period, the discounted incremental cost-effectiveness ratio
(iCER) was €28.019 per life year saved. For the subgroup analy-
ses 50–54, 55–59 and 60–64 the iCERs were estimated at
€44.558; €37.632 and €15.810 per life year saved. The net
budget impact following an expansion of the vaccination
program with healthy adults 50-was estimated at 18 million
euros annually. In case the summer would be used as the refer-
ence period, the discounted iCER was €9.421 per life year saved.
For the subgroup analyses 50–54, 55–59 and 60–64 the iCER
were estimated at €19.036; €11.151 and €4.314 per life year
saved. The net budget impact following would amount to 12.9
million euros annually. CONCLUSION: The iCER depended on
the reference period chosen in the analyses. Subsequent policy
decisions making could as a result lead to different outcomes.
Based on the most conservative estimates, the iCER fell below
€20.000 per life year gained only for healthy adults aged 60–65.
With the summer as reference period, the entire age cohort 50–64
fell below €20,000 per life year gained.
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OBJECTIVES: Develop a multinational, cross-sectional pneumo-
coccal disease health state model to examine the expected out-
comes, costs, and incremental cost-effectiveness ratio (ICER)
among children vaccinated with PCV7 and unvaccinated adults.
METHODS: A cost-effectiveness analysis was performed to
compare costs and outcomes attributable to invasive pneumo-
coccal disease (IPD) and non-IPD for vaccinated and unvacci-
nated birth cohorts in each country/region studied. The model
also accounted for indirect (herd immunity) effects among
unvaccinated adults using country/region-speciﬁc assumptions
and estimates, which included taking a conservative approach
excluding indirect effects on pneumonia in the US and Latin
America. The following disease states were modeled: meningitis,
bacteremia, inpatient pneumonia, outpatient pneumonia, and in
children only, otitis media (both mild and moderate/severe).
Country-speciﬁc estimates for population data, incidence rates,
serotype coverage and replacement, mortality rates, vaccine efﬁ-
cacy rates, direct medical and non-medical and indirect costs
were derived from the literature and previously conducted health
economic assessments of PCV7 to populate the economic model.
Additionally, an analysis was conducted using recently published
US data on reduction of pneumonia hospitalizations and otitis
media visits following the availability of PCV7. RESULTS: The
societal ICER in the US was $111,266/life year gained (LYG)
when only considering direct effects, which decreased to $4,226/
LYG after including indirect effects. Incorporating the new data
on otitis media and pneumonia decreased the direct effects only
ICER to $13,614/LYG and was cost saving when indirect effects
were included. For other countries, the societal ICERs account-
ing for indirect effects were 21,799 CAD/LYG in Canada, 72,505
SFr/LYG in Switzerland, and $6,971/LYG in Latin America.
CONCLUSION: Vaccination with PCV7 is cost-effective in all of
the countries studied when accounting for indirect effects among
adults. Furthermore, PCV7 is cost saving among the US popula-
tion when incorporating recent data on pneumonia and otitis
media.
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OBJECTIVES: Introduction of a quadrivalent human papilloma-
virus (HPV-types 6, 11, 16, 18) vaccine is expected to signiﬁ-
cantly reduce the burden of cervical cancer (CC), cervical lesions
(CIN), genital warts (GW) and other HPV-related diseases. The
objective of this study is to assess the health and economic impact
in Belgium of implementing a quadrivalent HPV vaccination
programme alongside screening practices versus screening alone.
METHODS: A Markov model, developed to examine the epide-
miological and economic impact of a universal HPV vaccination,
was adapted to the Belgian situation, reﬂecting the local screen-
ing and treatment pathways and local epidemiological and cost
data. A lifetime horizon was applied. A vaccine that would
prevent 100% of HPV 6,11,16, and 18-associated disease, with
lifetime efﬁcacy duration, 80% coverage and costing 441.63€ per
vaccination course, given to girls at age 12 in conjunction with
current screening, was compared to screening alone. For this
analysis, 35% of CIN1, 55% of CIN2/3, 75% of CC, and 90%
of GW were considered attributable to HPV types 6, 11, 16, and
18. The model adopted the perspective of the Belgian Health
Care Payer. Robustness of results to key parameters was explored
through a series of one-way sensitivity analyses. RESULTS:
Introduction of vaccination with a quadrivalent HPV vaccine
alongside current screening practices is expected to further
reduce the lifetime risk of cervical cancer of almost 50%. Vacci-
nation alongside the current screening programme is associated
with an incremental cost-effectiveness ratio of €13,756/LYG and
€10,546/QALY. This is within the accepted range of cost-effective
interventions in Europe. Results were most sensitive to discount
rate and efﬁcacy duration but, even in the worst case, ratios were
still under €50,000/QALY. CONCLUSION: These analyses
suggest that adding a quadrivalent HPV vaccine to the current
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